These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12665805)

  • 1. UK bidding war amidst merger mania.
    Mitchell P
    Nat Biotechnol; 2003 Apr; 21(4):343-4. PubMed ID: 12665805
    [No Abstract]   [Full Text] [Related]  

  • 2. Splurge or merge?
    Jacobs T
    Nat Biotechnol; 2003 May; 21(5):485. PubMed ID: 12721563
    [No Abstract]   [Full Text] [Related]  

  • 3. UK industry consolidation is slow despite big merger.
    Mitchell P
    Nat Biotechnol; 2003 Mar; 21(3):215. PubMed ID: 12610553
    [No Abstract]   [Full Text] [Related]  

  • 4. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 5. Antisoma-Roche deal--a new kind of buyout?
    Mitchell P
    Nat Biotechnol; 2003 Jan; 21(1):3. PubMed ID: 12511894
    [No Abstract]   [Full Text] [Related]  

  • 6. Fight, copy or cooperate? How hospitals can respond to poaching by PPMs.
    Coddington DC; Moore KD; Fischer EA
    Healthc Forum J; 1998; 41(4):44-6, 48. PubMed ID: 10185472
    [No Abstract]   [Full Text] [Related]  

  • 7. Start-ups weigh benefits of corporate incubators.
    Waltz E
    Nat Biotechnol; 2008 Mar; 26(3):254-5. PubMed ID: 18327219
    [No Abstract]   [Full Text] [Related]  

  • 8. Patents and investors.
    Carter S
    Med Device Technol; 2004 Apr; 15(3):11. PubMed ID: 15255529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. UK biotech sector loses flagship PowderJect to Chiron.
    Mitchell P
    Nat Biotechnol; 2003 Jul; 21(7):717. PubMed ID: 12833073
    [No Abstract]   [Full Text] [Related]  

  • 10. Evolving symbiosis--venture capital and biotechnology.
    Bradford TC
    Nat Biotechnol; 2003 Sep; 21(9):983-4. PubMed ID: 12949556
    [No Abstract]   [Full Text] [Related]  

  • 11. Legacy, Abbott-Northwestern use systems thinking concepts to hone competitive strategy.
    Southwick K
    Strateg Healthc Excell; 1996 Oct; 9(10):1-7. PubMed ID: 10161461
    [No Abstract]   [Full Text] [Related]  

  • 12. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 13. Biotechs await single European financial market.
    Louët S
    Nat Biotechnol; 2003 Dec; 21(12):1417. PubMed ID: 14647312
    [No Abstract]   [Full Text] [Related]  

  • 14. Think globally, manage locally.
    Coile RC
    Health Syst Rev; 1997; 30(3):20-3. PubMed ID: 10168602
    [No Abstract]   [Full Text] [Related]  

  • 15. Commercializing biotechnology in the UK.
    Searle S; Graves B; Towler C
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE33-5. PubMed ID: 12874976
    [No Abstract]   [Full Text] [Related]  

  • 16. Project risk evaluation in a multihospital system.
    Widman JP
    Top Health Care Financ; 1992; 19(1):58-67. PubMed ID: 1529437
    [No Abstract]   [Full Text] [Related]  

  • 17. Can your hospital remain independent?
    Byrd CW; McCue MJ
    Healthc Financ Manage; 2003 Sep; 57(9):40-4. PubMed ID: 14503142
    [No Abstract]   [Full Text] [Related]  

  • 18. This means war.
    Nat Biotechnol; 2008 Sep; 26(9):954. PubMed ID: 18779784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Filters for preparing to meet a venture capitalist.
    Christoffersen R
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE49-50. PubMed ID: 12874981
    [No Abstract]   [Full Text] [Related]  

  • 20. Texas health resources shows a proactive merger can pay off.
    Worrell B
    Health Care Strateg Manage; 2003 Sep; 21(9):9-11. PubMed ID: 14524172
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.